Lyell Immunopharma (NASDAQ:LYEL) Downgraded by Wall Street Zen to “Sell”

Lyell Immunopharma (NASDAQ:LYEL) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

LYEL has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday. Stifel Nicolaus assumed coverage on Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 price objective for the company. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial initiated coverage on shares of Lyell Immunopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Lyell Immunopharma in a research note on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.86.

Lyell Immunopharma Trading Down 0.9%

Shares of NASDAQ:LYEL opened at $8.12 on Friday. The stock’s 50-day moving average price is $11.95 and its 200-day moving average price is $15.06. Lyell Immunopharma has a 12-month low of $7.20 and a 12-month high of $45.00. The stock has a market capitalization of $198.94 million, a P/E ratio of -0.63 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, research analysts predict that Lyell Immunopharma will post -7.16 EPS for the current year.

Institutional Trading of Lyell Immunopharma

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC increased its position in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after purchasing an additional 76,921 shares during the period. Opaleye Management Inc. lifted its position in shares of Lyell Immunopharma by 334.9% in the 2nd quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after purchasing an additional 264,928 shares during the period. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma in the 2nd quarter worth about $4,744,643. Dimensional Fund Advisors LP purchased a new stake in shares of Lyell Immunopharma in the 1st quarter worth about $959,000. Finally, Squarepoint Ops LLC boosted its stake in shares of Lyell Immunopharma by 119.4% during the 2nd quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock valued at $595,000 after purchasing an additional 23,028 shares in the last quarter. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for cancer, with an emphasis on solid tumors. The company seeks to address limitations of existing cell therapies, including T-cell exhaustion, limited persistence and reduced activity within the tumor microenvironment.

Lyell uses cell-engineering and genomic technologies to develop investigational chimeric antigen receptor (CAR) T-cell and T-cell receptor (TCR) therapies.